Where have we got to? REG, the first few months: Alison Chisholm.
-
Upload
corey-harris -
Category
Documents
-
view
215 -
download
1
Transcript of Where have we got to? REG, the first few months: Alison Chisholm.
![Page 1: Where have we got to? REG, the first few months: Alison Chisholm.](https://reader035.fdocuments.in/reader035/viewer/2022062714/56649cfe5503460f949cfa9f/html5/thumbnails/1.jpg)
Where have we got to?REG, the first few months: Alison Chisholm
![Page 2: Where have we got to? REG, the first few months: Alison Chisholm.](https://reader035.fdocuments.in/reader035/viewer/2022062714/56649cfe5503460f949cfa9f/html5/thumbnails/2.jpg)
Initial wish
“Set up a new initiative that will raise the quality and profile of real-life (respiratory) research across the research, political and public arenas”
![Page 3: Where have we got to? REG, the first few months: Alison Chisholm.](https://reader035.fdocuments.in/reader035/viewer/2022062714/56649cfe5503460f949cfa9f/html5/thumbnails/3.jpg)
• Set up an independent social enterprise • Invite the right people
o Core steering group– Reactive– Rapid-decision makers
o Wider expert membership• Contact sponsors• Begin dialogue and discussion among the members• Build “web-presence”• Undertake research – starting with a validation study• Bring the lead group together to set an action plan
![Page 4: Where have we got to? REG, the first few months: Alison Chisholm.](https://reader035.fdocuments.in/reader035/viewer/2022062714/56649cfe5503460f949cfa9f/html5/thumbnails/4.jpg)
The beginnings of REG
• Work began on the 1st of October 2012
• As of 1st February, the Respiratory Effectiveness Group is trading as a social enterprise organisation
(formally as Respiratory Effectiveness Ltd)
![Page 5: Where have we got to? REG, the first few months: Alison Chisholm.](https://reader035.fdocuments.in/reader035/viewer/2022062714/56649cfe5503460f949cfa9f/html5/thumbnails/5.jpg)
How have we done: members?
15 core steering committee members; 44 extended members = 59 world experts united
so far
Australia: 2
Canada: 2
China: 1Hong Kong: 2Singapore: 1
USA: 12
South Africa: 1
![Page 6: Where have we got to? REG, the first few months: Alison Chisholm.](https://reader035.fdocuments.in/reader035/viewer/2022062714/56649cfe5503460f949cfa9f/html5/thumbnails/6.jpg)
Member details: extended group
![Page 7: Where have we got to? REG, the first few months: Alison Chisholm.](https://reader035.fdocuments.in/reader035/viewer/2022062714/56649cfe5503460f949cfa9f/html5/thumbnails/7.jpg)
• Emails• Newsletters• LinkedIn group• Twitter account (RepirEffect)• Face-to-face meetings… •Web-based discussions
Keeping members engaged
![Page 8: Where have we got to? REG, the first few months: Alison Chisholm.](https://reader035.fdocuments.in/reader035/viewer/2022062714/56649cfe5503460f949cfa9f/html5/thumbnails/8.jpg)
Web presence
•Due for launch… any day•Designed to allow continual updates• Pages to display:• Research• Related-literature• REG activities• News updates• Membership / join• Sponsors / support us• Register your study
![Page 9: Where have we got to? REG, the first few months: Alison Chisholm.](https://reader035.fdocuments.in/reader035/viewer/2022062714/56649cfe5503460f949cfa9f/html5/thumbnails/9.jpg)
Website
![Page 10: Where have we got to? REG, the first few months: Alison Chisholm.](https://reader035.fdocuments.in/reader035/viewer/2022062714/56649cfe5503460f949cfa9f/html5/thumbnails/10.jpg)
Sponsors: confirmed• Research in Real Life: code lists and expertise
• Optimum Patient Care: free dataset access (to the Optimum Patient Care Research Database)
• Teva: unrestricted grant for set up with assurance of on-going support for 4 years.
• Boehringer Ingelheim: pledged support (covering ~one-fifth of annual projected costs) for years 1–4 of the initiative
![Page 11: Where have we got to? REG, the first few months: Alison Chisholm.](https://reader035.fdocuments.in/reader035/viewer/2022062714/56649cfe5503460f949cfa9f/html5/thumbnails/11.jpg)
Aligned with their corporate policy and current thinking:•Chiesi: spoke with Corporate Head of Respiratory and Primary and Medical Lead on Monday•Merck: Office of the Chief Medical Officer at Merck has signaled they are interested in the proposal. A number of questions were asked in early Jan which are now being considered•Smaller pockets, but have noted interest
o Aerocrineo Kyorino Mundipharma
Under review (since 24 Jan):•Pfizer: Marc Berger, VP of Real World Data and Analytics•GSK: David Leather Vice President and Global Medical Affairs Leader – Relvar•Novartis: Keith Allen, Director Global Advocacy•Stallergenes: Under review by the Medical Information Management team with a view to discussing it with the Medical Directors
No contact as yet with: AstraZeneca, Sunovion, Genentech
Sponsors: in discussion